[1]
|
P. Picci, “Osteosarcoma (Osteogenic Sarcoma),” Orpha-net Journal of Rare Diseases, Vol. 2, 2007, p. 6.
doi:10.1186/1750-1172-2-6
|
[2]
|
T. A. Damron, W. G. Ward and A. Stewart, “Osteosarcoma, Chondrosarcoma, and Ewing’s Sarcoma: National Cancer Data Base Report,” Clinical Orthopaedics and Related Research, Vol. 459, 2007, pp. 40-47.
doi:10.1097/BLO.0b013e318059b8c9
|
[3]
|
D. Bonnet and J. E. Dick, “Human Acute Myeloid Leukemia Is Organized as a Hierarchy that Originates from a Primitive Hematopoietic Cell,” Nature Medicine, Vol. 3, 1997, pp. 730-737. doi:10.1038/nm0797-730
|
[4]
|
D. Hanahan and R. A. Weinberg, “The Hallmarks of Cancer,” Cell, Vol. 100, No. 1, 2000, pp. 57-70.
doi:10.1016/S0092-8674(00)81683-9
|
[5]
|
T. Reya, S. J. Morrison, M. F. Clarke and I. L. Weissman, “Stem Cells, Cancer, and Cancer Stem Cells,” Nature, Vol. 414, No. 6859, 2001, pp. 105-111.
doi:10.1038/35102167
|
[6]
|
B. Vogelstein and K. W. Kinzler, “Cancer Genes and the Pathways They Control,” Natural Medicine, Vol. 10, No. 8, 2004, pp. 789-799. doi:10.1038/nm1087
|
[7]
|
L. Wang, P. Park and C. Y. Lin, “Characterization of Stem Cell Attributes in Human Osteosarcoma Cell Lines,” Cancer Biology & Therapy, Vol. 8, No. 6, 2009, pp. 543- 552. doi:10.4161/cbt.8.6.7695
|
[8]
|
L. Wang, P. Park, H. Zhang, F. La Marca and C. Y. Lin, “Prospective Identification of Tumorigenic Osteosarcoma Cancer Stem Cells in OS99-1 Cells Based on High Aldehyde Dehydrogenase Activity,” International Journal of Cancer, Vol. 128, No. 2, 2011, pp. 294-303.
doi:10.1002/ijc.25331
|
[9]
|
A. M. Cheung, T. S. Wan, J. C. Leung, L.Y. Chan, H. Huang, Y. L. Kwong, R. Liang and A. Y. Leung, “Aldehyde Dehydrogenase Activity in Leukemic Blasts Defines a Subgroup of Acute Myeloid Leukemia with Adverse Prognosis and Superior NOD/SCID Engrafting Potential,” Leukemia, Vol. 21, 2007, pp. 1423-1430.
doi:10.1038/sj.leu.2404721
|
[10]
|
C. Ginestier, M. H. Hur, E. Charafe-Jauffret, F. Monville, J. Dutcher, M. Brown, J. Jacquemier, P. Viens, C. G. Kleer, S. Liu, A. Schott, D. Hayes, D. Birnbaum, M. S. Wicha and G. Dontu, “ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical Outcome,” Cell Stem Cell, Vol. 1, No. 5, 2007, pp. 555-567. doi:10.1016/j.stem.2007.08.014
|
[11]
|
E. H. Huang, M. J. Hynes, T. Zhang, C. Ginestier, G. Dontu, H. Appelman, J. Z. Fields, M. S. Wicha, B. M. Boman, “Aldehyde Dehydrogenase 1 Is a Marker for Normal and Malignant Human Colonic Stem Cells (SC) and Tracks SC Overpopulation during Colon Tumorigenesis,” The Journal of Cancer Research, Vol. 69, 2009, pp. 3382-3389. doi:10.1158/0008-5472.CAN-08-4418
|
[12]
|
M. B. Kastan, E. Schlaffer, J. E. Russo, O. M. Colvin, C. I. Civin and J. Hilton, “Direct Demonstration of Elevated Aldehyde Dehydrogenase in Human Hematopoietic Progenitor Cells,” Blood, Vol. 75, No. 10, 1990, pp. 1947- 1950.
|
[13]
|
S. Ma, K. W. Chan, T. K. Lee, K. H. Tang, J. Y. Wo, B. J. Zheng and X. Y. Guan, “Aldehyde Dehydrogenase Discriminates the CD133 Liver Cancer Stem Cell Populations,” Molecular Cancer Research, Vol. 6, 2008, pp. 1146-1153. doi:10.1158/1541-7786.MCR-08-0035
|
[14]
|
N. E. Sladek, R. Kollander, L. Sreerama and D. T. Kiang, “Cellular Levels of Aldehyde Dehydrogenases (ALD- H1A1 and ALDH3A1) as Predictors of Therapeutic Responses to Cyclophosphamide-Based Chemotherapy of Breast Cancer: A Retrospective Study. Rational Individualization of Oxazaphosphorine-Based Cancer Chemotherapeutic Regimens,” Cancer Chemotherapy and Pharmacology, Vol. 49, No. 4, 2002, pp. 309-321.
doi:10.1007/s00280-001-0412-4
|
[15]
|
L. Wang, P. Park, H. Zhang, F. La Marca, A. Claeson, J. Valdivia and C. Y. Lin, “BMP-2 Inhibits the Tumorigenicity of Cancer Stem Cells in Human Osteosarcoma OS99-1 Cell Line,” Cancer Biology Therapy, Vol. 11, No. 5, 2011 pp. 457-463. doi:10.4161/cbt.11.5.14372
|